GV-971 for Alzheimer's Disease (GREEN MEMORY Trial)

"The sponsor, Shanghai Greenvalley Pharmaceutical Co., Ltd., needs to recruit 2046 individuals that meet the clinical trial's inclusion criteria from multiple locations including Diex Recherche Sherbrooke/Site 1001 in Sherbrooke, Quebec and The Cognitive Research Center of New jersey / Site 1157 in Springfield, New Jersey."

"The primary outcome for this study, which will be observed at Baseline, 48 weeks, and 52 weeks, is the Change from baseline in ADCS-CGIC score. Additionally, this trial will observe secondary outcomes includingChange from baseline in NPI score and Change from baseline on Alzheimer's disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) scale total score. The efficacy of GV-971 throughout the OLE period will also be assessed."

"In addition to Diex Recherche Sherbrooke/Site 1001 in Sherbrooke, Quebec, The Cognitive Research Center of New jersey / Site 1157 in Springfield, New Jersey, and Clinical Trials of Texas; Inc in San Antonio, Texas this trial is also taking place at 100 other research facilities."

"The Power team believes that GV-971 is a safe medication because it has progressed to Phase 3 clinical trials. This means that there is data supporting both its efficacy and safety."

"This clinical study is looking for 2046 individuals that have a diagnosis of Alzheimer's disease, are between 50-85 years old, and meet the following additional requirements: evidence of cognitive decline over the course of at least one year per NIA-AA guidelines, must have a designated caregiver, and a baseline Mini–Mental State Examination (MMSE) score between 11 and 24."

"According to the age requirements set forth by this trial, the minimum age for enrollment is 50 and the maximum age is 85."

"The clinical trial, which was posted on October 27th 2020 and updated most recently on December 10th 2021, is still looking for participants according to information found on clinicaltrials.gov"